Image-generating AI seems to be stuck between a rock and a hard place. To work

A takahe pair were released near Wellington in a victory for efforts to save some of the world's rarest birds.

Welcome to Money Diaries where we are tackling the ever-present taboo that is money. We’re asking real people how they spend their hard-earned money during a seven-day period — and we’re tracking every last dollar.

TL;DR: Livestream the 2023 Berlin Marathon for free on Watch Athletics. There are hundreds of

Vineyards and apple orchards across the Northeast are still gauging damage from a late-season frost in May that wiped out a third to most of the crop for some growers who say it's the worst frost damage they've ever seen

Popeyes Louisiana Kitchen’s sales boomed when it launched the chicken sandwich that broke the internet. It’s now betting

DoorDash set new records for total orders and revenue in the second quarter as its grocery and convenience deliveries accelerated and it improved driver efficiency

High school students’ scores on the ACT college admissions test have dropped to their lowest in more than three decades, showing a lack of student preparedness for college-level coursework, according to the nonprofit organization that administers the test

If Quordle is a little too challenging today, you've come to the right place for

Burger King in Thailand have launched a bizarre new product - a “real cheeseburger” made with 20 slices of American cheese and no meat. The Thai operator of the US fast food chain announced that the burger was available at its outlets nationwide starting Sunday 9 July. Footage shows burger-lover Thanaporn Chatcharaporn, 26, tucking into the dish at a branch in Bangkok. “It’s very, very salty. Almost too salty to eat. The smell is also very strong. At the first bite, it gave me goosebumps, but I couldn’t finish the whole thing. I wanted to try it just to see what it was like,” she said. The glorified cheese sandwich costs around $3 - slightly cheaper than a regular meat cheeseburger. Read More Two teens found illegally smuggled in boot of car in Texas Passenger gets ‘private’ jet for £188 as no other travellers board flight Cancer survivor wears glittering eyeballs after losing left eye as baby

Using existing drugs to treat cervical cancer before standard treatment could lead to a 35% reduction in the risk of relapse or death, a new study suggests. Researchers from the UCL Cancer Institute and UCLH looked into whether a short course of induction chemotherapy (IC), where a drug is used to destroy as many cancer cells as possible, before chemoradiation (CRT), could help with this. Here’s everything you need to know about the findings… What is cervical cancer? According to the NHS website, cervical cancer is a type of cancer found anywhere near the cervix – the opening between the vagina and the womb (uterus), which is also known as the neck of the womb. Most cervical cancers grow very slowly and are caused by an infection from specific types of human papillomavirus (HPV) and mostly affect women under the age of 45. According to Jo’s Cervical Cancer Trust, symptoms include vaginal bleeding that is unusual to you, changes to vaginal discharge, discomfort during sex and pain in your lower back or pelvis. Changes to cells can be spotted by a cervical screening, and then treated before they turn into cancer. There are around 3,200 new cases every year in the UK, with the five-year survival rate being around 70%, according to Cancer Research UK. CRT has been the standard treatment for cervical cancer patients since 1999, but even though there have been overall significant developments in radiation therapy techniques, up to 30% of people experience their cancer coming back. What did the research involve? Over a 10-year period, 500 patients who had been diagnosed with cervical cancer – that was large enough to see without a microscope but hadn’t spread to other parts of the body – took part in the Interlace trial at hospitals in the UK, Mexico, India, Italy and Brazil. Researchers looked into whether a short course of IC before CRT could reduce rates of relapse and death. What results were found? After five years, researchers discovered that 80% of the people who received a combination of chemotherapy and radiotherapy were alive, whilst 73% had not seen their cancer return or spread. A major benefit, according to researchers, is that it can be incorporated into standard of care treatment relatively quickly, because cheap, accessible and already-approved ingredients such as carboplatin and paclitaxel are needed for IC. “Our trial shows that this short course of additional chemotherapy delivered immediately before the standard CRT can reduce the risk of the cancer returning or death by 35%,” said Dr Mary McCormack, lead investigator of the trial from UCL Cancer Institute and UCLH. “This is the biggest improvement in outcome in this disease in over 20 years. “I’m incredibly proud of all the patients who participated in the trial; their contribution has allowed us to gather the evidence needed to improve treatment of cervical cancer patients everywhere. “We couldn’t have done this without the generous support of Cancer Research UK.” Why is the research important? Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: “Timing is everything when you’re treating cancer. The simple act of adding induction chemotherapy to the start of chemoradiation treatment for cervical cancer has delivered remarkable results in this trial. “A growing body of evidence is showing the value of additional rounds of chemotherapy before other treatments like surgery and radiotherapy in several other cancers. “Not only can it reduce the chances of cancer coming back, it can be delivered quickly using drugs already available worldwide. “We’re excited for the improvements this trial could bring to cervical cancer treatment and hope short courses of induction chemotherapy will be rapidly adopted in the clinic.”

The modern Y2K style resurgence has brought with it the ingenious reuse of the decade's